COVIS Company Profile

✉ Email this page to a colleague

COVIS has eleven approved drugs.

There are five US patents protecting COVIS drugs.

There are one hundred and forty-four patent family members on COVIS drugs in forty-six countries and twenty-seven supplementary protection certificates in fourteen countries.

International Patents:	144
US Patents:	5
Tradenames:	12
Ingredients:	9
NDAs:	11
Patent Litigation for COVIS:	See patent lawsuits for COVIS

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	LANOXIN	digoxin	INJECTABLE;INJECTION	009330-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes	RE46417	⤷ Subscribe	Y	Y		⤷ Subscribe
Covis	ALTOPREV	lovastatin	TABLET, EXTENDED RELEASE;ORAL	021316-002	Jun 26, 2002		RX	Yes	No		⤷ Subscribe				⤷ Subscribe
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes	11,000,517	⤷ Subscribe	Y			⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012	10,034,867	⤷ Subscribe
Covis	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-001	Feb 2, 1995	4,703,038	⤷ Subscribe
Covis	ALTOPREV	lovastatin	TABLET, EXTENDED RELEASE;ORAL	021316-001	Jun 26, 2002	5,916,595	⤷ Subscribe
Covis	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019	10,588,895	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	30 mg/mL, 17 mL single-use vials	➤ Subscribe	2015-12-04
➤ Subscribe	Extended-release Tablets	20 mg and 30 mg	➤ Subscribe	2007-11-07
➤ Subscribe	Extended-release Tablets	40 mg	➤ Subscribe	2007-06-11
➤ Subscribe	Nasal Spray	250 mcg	➤ Subscribe	2012-02-13
➤ Subscribe	Extended-release Tablets	25.5 mg and 34 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	8.5 mg and 17 mg	➤ Subscribe	2009-03-02

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009112274	⤷ Subscribe
South Korea	100854321	⤷ Subscribe
Cyprus	1116926	⤷ Subscribe
European Patent Office	1670482	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1200431	2013/002	Ireland	⤷ Subscribe	PRODUCT NAME: ACLIDINIUM SALT WITH A PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; NAT REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720; FIRST REGISTRATION NO/DATE: EU/1/12/781/001-003 20/07/2012 EUROPEAN UNION EU/1/12/778/001-003 20/07/2012 EUROPEAN UNION EU/1/12/781/001-003 20120720
1169062	92114	Luxembourg	⤷ Subscribe	PRODUCT NAME: FERUMOXYTOL
0984957	2012/048	Ireland	⤷ Subscribe	PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
1169062	C01169062/01	Switzerland	⤷ Subscribe	PRODUCT NAME: FERUMOXYTOL; REGISTRATION NO/DATE: SWISSMEDIC 62033 17.08.2012
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.